Skip to content

Inflammatory Response Under Spinal vs General Anesthesia in PCNL: NLR, RDW, LAR.

Effects of Spinal Versus General Anesthesia on Perioperative Inflammatory Response in Percutaneous Nephrolithotomy (PCNL): The Role of Neutrophil-to-Lymphocyte Ratio (NLR), Red Cell Distribution Width (RDW), and Lactate-to-Albumin Ratio (LAR)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07205224
Acronym
SAGEPCNL
Enrollment
90
Registered
2025-10-03
Start date
2025-09-22
Completion date
2025-10-22
Last updated
2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrolithiasis, Postoperative Inflammation

Keywords

Percutaneous Nephrolithotomy, PCNL, Spinal Anesthesia, General Anesthesia, Inflammatory Response, Neutrophil-to-Lymphocyte Ratio (NLR), Red Cell Distribution Width (RDW), Lactate-to-Albumin Ratio (LAR)

Brief summary

This observational study compares the effects of spinal versus general anesthesia on the perioperative systemic inflammatory response in adults undergoing PCNL. Routine clinical laboratory values (NLR, RDW, LAR) obtained preoperatively and postoperatively will be recorded to evaluate between-group and within-group changes. No additional blood sampling will be performed beyond standard care.

Detailed description

The study will be conducted at the Department of Anesthesiology and Reanimation, Elazığ Fethi Sekin City Hospital, among adult patients scheduled for PCNL (ASA I-III). The anesthesia type (spinal vs general) is determined by clinical requirements; investigators do not influence this choice. Sampling windows: Preoperative: within ≤6 hours before surgery Postoperative: first sample obtained within 6-24 hours after surgery Parameters: NLR (neutrophil/lymphocyte), RDW, LAR; plus age, sex, ASA class, operative time, and in-hospital complications. Statistics: Normality testing; between-group comparisons by independent t-test or Mann-Whitney U; within-group by paired t-test or Wilcoxon; categorical by chi-square; p\<0.05 significant. Power considerations target ≥45 per group (total ≥90). No extra biospecimens will be collected beyond routine care.

Interventions

Patients receive either spinal or general anesthesia according to routine clinical decision-making. No investigational drug or device is administered.

Sponsors

Sevim Şenol Karataş
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

Age ≥18 years ASA physical status I-III Scheduled for percutaneous nephrolithotomy (PCNL) Provided informed consent

Exclusion criteria

Active infection or sepsis Known malignancy Chronic inflammatory or autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) Current immunosuppressive therapy Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change in Neutrophil-to-Lymphocyte Ratio (ΔNLR)Baseline (≤6 hours preoperative) and 24 hours postoperativelyDifference in neutrophil-to-lymphocyte ratio (NLR) between preoperative (≤6 hours before surgery) and postoperative (6-24 hours after surgery) blood samples in spinal vs general anesthesia groups.

Secondary

MeasureTime frameDescription
Change in Red Cell Distribution Width (ΔRDW)Baseline (≤6 hours preoperative) and 24 hours postoperativelyDifference in RDW values between preoperative (≤6 hours before surgery) and postoperative (6-24 hours after surgery) blood samples in spinal vs general anesthesia groups.
Change in Lactate-to-Albumin Ratio (ΔLAR)aseline (≤6 hours preoperative) and 24 hours postoperativelyDifference in LAR values between preoperative (≤6 hours before surgery) and postoperative (6-24 hours after surgery) blood samples in spinal vs general anesthesia groups.
Postoperative ComplicationsFrom surgery until hospital discharge (up to 7 days)Occurrence of any PCNL-related complications (e.g., bleeding, infection) during index hospitalization.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026